marcus schmidt - Gynecology

Author Information

Marcus Schmidt is affiliated with the University Medical Center Mainz, Department of Gynecology, located at Langenbeckstr. 1, Mainz, 55131, Germany. His research spans various aspects of gynecology and oncology, with a particular focus on breast cancer and cervical cancer treatment modalities.

Research Contributions

Marcus Schmidt has made significant contributions to the field of gynecology and oncology. His research encompasses various aspects of cancer treatment, including the efficacy of immunotherapy in cervical cancer, the comparison of radiosensitizers in vulvar cancer treatment, and the evaluation of adjuvant therapies in breast cancer. Notably, he has been involved in several high-impact studies, such as the ELEANOR and SASCIA studies, which investigate treatment options for HER2-positive and HER2-negative breast cancer patients, respectively. His work also extends to the study of endocrine therapy in men with breast cancer and the assessment of informed consenting processes in cancer treatment.

Aliases

Marcus Schmidt

Publication and Citation Metrics

Metric	Value
Citation Count	10,594
H-index	46
Paper Count	268

Publications:

Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib

DOI: 10.1158/1538-7445.sabcs21-p2-13-30

Year: 2022

Abstract OT1-02-01: Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA

DOI: 10.1158/1538-7445.sabcs21-ot1-02-01

Year: 2022

Efficacy and Safety of Immunotherapy for Cervical Cancer—A Systematic Review of Clinical Trials

DOI: 10.3390/cancers14020441

Year: 2022

Comparison of cisplatin and mitomycin C/5-FU as radiosensitisers in the treatment of locally advanced vulvar cancer: results of a retrospective, observational, single-institutional cohort study

DOI: 10.1007/s00432-022-04006-0

Year: 2022

Immuno-oncology in triple-negative breast cancer

DOI: 10.20517/2394-4722.2020.124

Year: 2021

Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.

DOI: 10.1001/jamaoncol.2020.7442

Year: 2021

Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center

DOI: 10.1007/s00432-020-03495-1

Year: 2021

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.

DOI: 10.1001/jamaoncol.2021.2193

Year: 2021

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

DOI: 10.1200/JCO.2021.39.15_SUPPL.TPS602

Year: 2021

Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.

DOI: 10.1016/j.ejca.2021.03.045

Year: 2021

How Can Pelvic Floor Disorders Be Prevented?

Can Hypertrichosis be Prevented?

How is Cortisol Related to Gynecology?

What Are the Treatment Options for Gynecological Conditions?

Can kidney infections affect reproductive health?

How Can Positioning be Optimized for Surgical Procedures?

How do Chromosomal Abnormalities Affect Fertility?

What is the Uterine Lining?

Can Women with Pulmonary Hypertension Undergo Gynecological Surgeries?

Why is Informational Support Important?

Partnered Content Networks

Relevant Topics